A
Alcista
Alcista · 25%BIOA
$4.73
Precio del escenario
$5.950
-0.010 (-0.17%)Al cierre
Loading chart…
- Máximo
- 6.300
- Apertura
- 6.030
- Precio medio ponderado por volumen
- 6.00
- Volumen
- 613.07K
- Capitalización
- —
- Mínimo
- 5.740
- Importe
- 3.68M
- EV/EBITDA, TTM
- -1.14
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Análisis de IA of BioAge Labs, Inc. (BIOA)
ComprarBIOA is a good buy right now due to its recent revenue growth of 1.7% year-over-year, achieving $2.45 million in Q2, and a current price of $5.80, which is significantly lower than its 52-week high of $25.95. The RSI of 56.26 indicates a neutral momentum, suggesting potential for upward movement. The main risk is the net loss of $26.09 million reported in Q2, which reflects ongoing profitability challenges.
Métricas de valoración
El PER previsto actual de BioAge Labs, Inc. (BIOA) es 0.00, frente a su media de 5 años de -2.98.
Escenarios de precio de Alphio AI para BIOA
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con BIOA en cartera
Cronología de eventos
Noticias
9.010-30NewsfilterBioArctic Appoints Nomination Committee for 2027 AGM
- 5.009-22Newsfilter
First Patient Treated with Leqembi® for Alzheimer's in Sweden
- 8.509-16Newsfilter
Leqembi Pen Approved in Japan for Alzheimer's Treatment
- 7.508-19Newsfilter
BioArctic and Mesenkia Enter Research Collaboration for Glioblastoma Treatment
- 9.508-19Newsfilter
BioArctic to Release Q2 2026 Report on August 26
Preguntas frecuentes sobre BIOA, respondidas por Alphio AI
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function. It operates in the Healthcare sector.
BIOA is a good buy right now due to its recent revenue growth of 1.7% year-over-year, achieving $2.45 million in Q2, and a current price of $5.80, which is significantly lower than its 52-week high of $25.95. The RSI of 56.26 indicates a neutral momentum, suggesting potential for upward movement. The main risk is the net loss of $26.09 million reported in Q2, which reflects ongoing profitability challenges.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.